Xtant Medical Expands Portfolio with CollagenX™ for Enhanced Wound Care

Published: 10 Nov 2025

Author: Precedence Research

Share :

Xtant Medical Holdings, Inc. is a premier global medical technology firm specializing in advanced surgical solutions for the spinal, orthopaedic, and wound care disorders. The commercial introduction of CollagenXtm, a novel bovine collagen particulate product, is designed to help engineers with surgical wound closure. The solution is designed to promote rapid healing, reduce skin shear, and lower the risk of surgical site infection, one of the most stubborn problems in post-operative care.

CollagenXtm is one of the milestones in Xtant Medical's broader mission to develop regenerative medicine based on new-generation biologics. The new product is designed to enable a large range of surgical applications. This helps Xtant market products expand its orthobiologic line and reiterate its focus on providing safe, effective, and scientifically advanced wound management products. CollagenX provides a natural collagen matrix that supports an optimal healing environment and assists clinicians in improving outcomes in both complex and routine surgical settings.

The launch of CollagenX by Xtant Medical comes at a pivotal moment, as healthcare professionals worldwide are increasingly prioritizing patient-centric and biologically driven treatment options. In today’s evolving medical landscape, regenerative medicine and advanced biologic technologies are reshaping traditional approaches to wound care. Products like CollagenX exemplify this transformation by combining natural biological components with cutting-edge biomedical engineering, offering more effective and holistic solutions for surgical wound healing and infection prevention. By integrating innovation with the body’s own regenerative processes, CollagenX represents a significant step forward in improving patient outcomes and enhancing the overall standard of care.

This development is a directional move by Xtant Medical, integrating scientific evidence with clinical practice to address gaps in surgical recovery and infection control. Furthermore, the company's extensive experience in biologic materials science and its emphasis on continuous improvement ensure that products such as CollagenX become the key to the future of surgical care.

Executive’s Statement

Sean Browne, President and CEO of Xtant Medical

The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, we are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes. CollagenX represents not only a new product but a step forward in redefining how we approach wound care and healing at a molecular level.